Perigon Wealth Management LLC Makes New Investment in Sera Prognostics, Inc. (NASDAQ:SERA)

Perigon Wealth Management LLC bought a new position in Sera Prognostics, Inc. (NASDAQ:SERA) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 85,185 shares of the company’s stock, valued at approximately $509,000. Perigon Wealth Management LLC owned approximately 0.27% of Sera Prognostics as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Frontier Wealth Management LLC bought a new position in shares of Sera Prognostics during the 1st quarter valued at about $30,000. Susquehanna International Group LLP purchased a new position in shares of Sera Prognostics in the first quarter valued at $39,000. Goldman Sachs Group Inc. purchased a new stake in Sera Prognostics during the first quarter valued at $41,000. Charles Schwab Investment Management Inc. bought a new position in Sera Prognostics during the first quarter valued at $46,000. Finally, Bank of New York Mellon Corp purchased a new position in shares of Sera Prognostics in the 1st quarter worth $50,000. Institutional investors own 54.64% of the company’s stock.

Insider Buying and Selling at Sera Prognostics

In other news, insider Paul Kearney sold 4,984 shares of the firm’s stock in a transaction dated Tuesday, February 6th. The shares were sold at an average price of $8.03, for a total value of $40,021.52. Following the completion of the sale, the insider now owns 160,066 shares in the company, valued at approximately $1,285,329.98. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In other Sera Prognostics news, insider Paul Kearney sold 4,984 shares of the stock in a transaction on Tuesday, February 6th. The stock was sold at an average price of $8.03, for a total value of $40,021.52. Following the sale, the insider now owns 160,066 shares in the company, valued at $1,285,329.98. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, insider John J. Boniface sold 21,438 shares of the business’s stock in a transaction on Tuesday, March 26th. The shares were sold at an average price of $9.55, for a total transaction of $204,732.90. Following the sale, the insider now directly owns 143,524 shares of the company’s stock, valued at $1,370,654.20. The disclosure for this sale can be found here. Insiders have sold 141,335 shares of company stock worth $1,255,192 over the last quarter. Insiders own 15.60% of the company’s stock.

Sera Prognostics Stock Up 3.9 %

Shares of NASDAQ:SERA opened at $10.04 on Tuesday. Sera Prognostics, Inc. has a 12 month low of $1.52 and a 12 month high of $11.32. The company has a 50-day moving average price of $9.20 and a 200 day moving average price of $5.74.

Sera Prognostics (NASDAQ:SERA) last announced its earnings results on Wednesday, March 20th. The company reported ($0.25) EPS for the quarter, hitting analysts’ consensus estimates of ($0.25). Sera Prognostics had a negative return on equity of 45.74% and a negative net margin of 11,843.79%. The firm had revenue of $0.04 million during the quarter, compared to analysts’ expectations of $0.10 million. Research analysts expect that Sera Prognostics, Inc. will post -0.94 earnings per share for the current fiscal year.

About Sera Prognostics

Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies.